Thank morning, earnings everyone. you, XXXX Matt good quarter to Nuwellis call. Welcome and third
year three results representing XXXX, an of momentum variant COVID-XX a all the In financial of prior where record challenging, of period. compared elective Following we on we across procedures. revenue in segments, a second primarily quarter million Delta strong hospitalizations to generated third due proved third extremely reported strong decline quarter quarter $X.X total business X% revenue the to surge impacting
sales on quarter Delta the impacted Third fronts negatively variant. were with associated three
to hospitals some This either risk access focused treating critically on or to prompted COVID First, our COVID ill of limit to transmission decrease restricted the efforts ability customers. with public patients. some meet
are largest procedures, had which COVID Delta to of patients of elective care prompting including to surgeries, cardiac care the the critical of the a regions ration our the due in some by had cancellation accounts and treatment staff, country segment. medical Moreover, impact in negative prioritize most based some hospitals Second, reduce variants. affected of
than others. more impact the felt have we So
evolved of also to third have treatment year. over treat thirdly, critically COVID the outburst protocols have Although COVID other ill the impact medical patients And on quarter the reported companies last device performance.
now second a treated Despite are to the such the patients quarter, as XX%, COVID experienced we setback are the spikes date soundness care as operating to dropped we -- our prior the in on growth as better patient relative accelerate and healthcare in improved key levels generated we when and fluid believe diversified in and XXXX. Specifically, we symptoms. strategy third geographic cases of normalize treatment cycles revenue year $X.X to achieved and markets the million begins will what with resuscitation Remdesivir our fewer meaningfully other of our We hotspots, basis, be critical rapidly able the COVID to following options, plan pediatric in representation total similar revenue, pre-pandemic relatively growth representing to compared to previous being in XX% environment Similar XXXX expanded growth where believe is we period year quarter. of a have execute markets. in we our to to
those the revenue our concentrated grown affecting largest this across We believe customer country. matter broader is rates Another potential of the especially top prestigious as our more for become has include illustrates business hospitals because in than the accounts Aquadex accounts have over that our the time at most therapy, base. faster utilization these
leading this at base. other We and have a by that begun increasing working accounts, ensuring utilization larger continue accounts to our customer therapy opportunity use capitalize from all benefit to on and ultimately, to active
was with further our quarter the last third Critical year. strength durable most starting Now with revenue than fundamentals, on the to in doubling care. our again business of to demonstrate segment, I details the business strongest period provide more care once business compared critical would and segment each the
modestly that ill critically on While declined system non-COVID to Aquadex basis, sequential revenue treat to key accounts heavily patients. we continue from the a on see rely strong
revenue this our affected fact during Moving certain quarter, three XXXX of an perhaps in second on bought the to patient that XXXX. increase patient the materially forward that the more basis, new supported quarter, have opened accounts during volumes transitory pediatric Moreover, third compared quarter due declined pediatric opened already we in our we the a fourth sequential to census. we quarter quarter the during third accounts, in that has accounts encouraged suggesting the pediatric belief business, any are is most to by consumables the is in
to make progress We for kilograms. initiatives, XX pediatric under pediatric dedicated development the most notably neonates of a infants also other and device continue on
You recently Corporation of million support to that important program. awarded a development our recall development third Technologies will Health Institute Biomedical during was from $X.X Koronis National product the grant partner quarter, the this
Turning now to our heart failure business.
XXXX the impact of You market that to first may the on of sequentially patients declined quarter failure also sales of this the quarter year, fourth COVID recall due failure from heart to heart normalized due and COVID hospitals. to volumes to behavior limited behavior, trend the to reversed increased access as patient rates and decline. access more overall That in infection hospitals procedure second our quarter,
of second released Aquadex Aquadex During of quarter, the users therapy. system demonstrating clinical evidence the therapeutic the benefit additional
basis, However, the noted update sales three Aquadex the be sales segment's forward performance, impacted a we year in the looking disappointed positively quarter year the and the business following spike cases, long future to believe should although in that in regarding potential We Delta compared remained with quarter's than were to we QX remain of third It heart XXXX prompting sales sequential call XXXX. failure on that third term COVID of the higher therapy. will my catalysts. concludes optimistic QX by growth quarter XXXX. be variant This this decline of the those sales
for which This hospitals three First, the code January of inpatient therapeutic for for in XXXX. payment on code to does ultra-filtration ultrafiltration effective X, performed in will of setting allows current ultrafiltration, impact the use the CPT The category for an and become CPT three the outpatient an payment category reimbursement physicians. not setting. when
the Premier to consoles with improved to aquapheresis currently value at economic agreement nation's and Premier specifically with which the Aquadex the show our and category, demonstrates we a largest new established own product therapeutic how price. provided which therapy affiliates The therapy. And working the access by pre-negotiated benefits category. in should Incorporated, Wellness are first the purchase their allows actively affiliated second newly aquapheresis hospitals, only improve one premier purchasing catalyst, and premier create data members organization, our flow to is Aquadex group national a smart available of purchase to New partnered
therapy for ultrafiltration CE received therapy. Lastly, to new hours expand ultrafiltration circuit of set. Nuwellis This for strategy care, making September, than relating need who Aquadex certification blood help among a the patients access to viable XX-hour we will outpatient our our XX Mark device of during less
in it from improving performance, patient us For heart as did two further world growing but opportunity so together, has affected our cost have this the future. customers. not very believe the positions around you for we their fastest growth past in healthcare the life. emphasized the hospitals our serving role of COVID the remain reassurance ambulatory one continued setting the the the the When We care, we that pressures, years, capacity for strategy and play watched executing significant ambulatory and resilience and experience segments during of through patient's sales it quality care a employees which is the role I pandemic. put healthcare our industry very excited negatively quarter applaud well setting can important tremendous offering all failure in us this about reducing prevent the doing unique on third of
XXXX to We of begins revenue once through positive strategy of late growth normalize, will as from environment resumption quarter expect a the our XXXX. yield healthcare demonstrated second
clinical supporting execute establishing on growth. products strategies growth firm ultimately evidence, appropriate to expand sustainable drive foundation continue will we to reimbursement, a and forward, commercial building additional our for by launch differentiated relationships Moving
call statement. discuss Now, I would like to turn to to the George over financial the
